The current study found that a DL model trained with weak labels for predicting TPS in a NSCLC cohort is capable of differentiating between tumor cells and immune cells in most of the cases and correctly quantifying the expression of PD-L1 in the specific tumor cells. This evidence concerns the gene CD274 and non-small cell lung carcinoma.